Home Pipeline

Overview

MacroGenics has a diverse portfolio of proprietary product candidates with several clinical trials currently underway or planned for the near future. Set forth below is the company’s development pipeline of product candidates for which we have retained commercialization or co-promotion rights in the U.S. or more broadly.

Program (Target)
Indications
Pre-IND Phase 1 Phase 2 Phase 3 Partner Our Commercial Rights
Oncology
Margetuximab (HER2) Green Cross Worldwide,
except Korea
Breast (3+) “SOPHIA”
placeholder
placeholder
placeholder
placeholder
Gastric (+anti-PD-1)
placeholder
placeholder
placeholder
Enoblituzumab (B7–H3) Worldwide
Solid Tumors (mono.)
placeholder
placeholder
Solid Tumors (+anti-CTLA-4)
placeholder
placeholder
Solid Tumors (+anti-PD-1)
placeholder
placeholder
Flotetuzumab (CD123 x CD3) Servier North America,
Japan, Korea, India
AML/MDS
placeholder
placeholder
MGD007 (gpA33 x CD3) Servier North America,
Japan, Korea, India
Colorectal
placeholder
placeholder
MGD011 (CD19 x CD3) Janssen U.S. Co-Promote1
B-cell Malignancies
placeholder
placeholder
MGD009 (B7-H3 x CD3) Worldwide
Solid Tumors
placeholder
placeholder
MGA012 (PD-1) Worldwide
Solid Tumors
placeholder
placeholder
MGD013 (PD-1 x LAG-3) Worldwide
Solid Tumors/Heme
placeholder
placeholder
AUTOIMMUNE & INFECTIOUS DISEASES
Teplizumab (CD3) NIDDK/NIH Worldwide
Type 1 Diabetes Prev.
placeholder
placeholder
placeholder
MGD010 (CD32B x CD79B) Worldwide
Autoimmune Disorders
placeholder
placeholder
MGD014 (HIV x CD3) NIAID/NIH Worldwide
HIV
placeholder

Oncology
Breast (3+) “SOPHIA”
Pre-IND Phase 1 Phase 2 Phase 3
placeholder
placeholder
placeholder
placeholder
Gastric (+anti-PD-1)
Pre-IND Phase 1 Phase 2 Phase 3
placeholder
placeholder
placeholder

PartnerGreen Cross
Our Commercial RightsWorldwide, except Korea
Solid Tumors (mono.)
Pre-IND Phase 1 Phase 2 Phase 3
placeholder
placeholder
Solid Tumors (+anti-CTLA-4)
Pre-IND Phase 1 Phase 2 Phase 3
placeholder
placeholder
Solid Tumors (+anti-PD-1)
Pre-IND Phase 1 Phase 2 Phase 3
placeholder
placeholder
Our Commercial RightsWorldwide
AML/MDS
Pre-IND Phase 1 Phase 2 Phase 3
placeholder
placeholder
PartnerServier
Our Commercial RightsNorth America, Japan, Korea, India
Colorectal
Pre-IND Phase 1 Phase 2 Phase 3
placeholder
placeholder
PartnerServier
Our Commercial RightsNorth America, Japan, Korea, India
B-cell Malignancies
Pre-IND Phase 1 Phase 2 Phase 3
placeholder
placeholder
PartnerJanssen
Our Commercial RightsU.S. Co-Promote1
Solid Tumors
Pre-IND Phase 1 Phase 2 Phase 3
placeholder
placeholder
Our Commercial RightsWorldwide
Solid Tumors
Pre-IND Phase 1 Phase 2 Phase 3
placeholder
placeholder
Our Commercial RightsWorldwide
Solid Tumors/Heme
Pre-IND Phase 1 Phase 2 Phase 3
placeholder
placeholder
Our Commercial RightsWorldwide
AUTOIMMUNE & INFECTIOUS DISEASES
Type 1 Diabetes Prev.
Pre-IND Phase 1 Phase 2 Phase 3
placeholder
placeholder
placeholder
PartnerNIDDK/NIH
Our Commercial RightsWorldwide
Autoimmune Disorders
Pre-IND Phase 1 Phase 2 Phase 3
placeholder
placeholder
Partner
Our Commercial RightsWorldwide
HIV
Pre-IND Phase 1 Phase 2 Phase 3
placeholder
PartnerNIAID/NIH
Our Commercial RightsWorldwide

(1) Option for U.S. co-promote; may elect to fund portion of late-stage development in exchange for U.S. and Canada profit share.

placeholdermAb placeholderDART

Please note – you will leave a website owned by MacroGenics, Inc.

MacroGenics is not responsible for any content on the third party website.

Ok Close